GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Solara Active Pharma Sciences Ltd (NSE:SOLARAPP) » Definitions » Enterprise Value

Solara Active Pharma Sciences (NSE:SOLARAPP) Enterprise Value : ₹41,382 Mil (As of Dec. 12, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Solara Active Pharma Sciences Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Solara Active Pharma Sciences's Enterprise Value is ₹41,382 Mil. Solara Active Pharma Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-3,388 Mil. Therefore, Solara Active Pharma Sciences's EV-to-EBIT ratio for today is -12.21.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Solara Active Pharma Sciences's Enterprise Value is ₹41,382 Mil. Solara Active Pharma Sciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-2,372 Mil. Therefore, Solara Active Pharma Sciences's EV-to-EBITDA ratio for today is -17.45.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Solara Active Pharma Sciences's Enterprise Value is ₹41,382 Mil. Solara Active Pharma Sciences's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was ₹11,713 Mil. Therefore, Solara Active Pharma Sciences's EV-to-Revenue ratio for today is 3.53.


Solara Active Pharma Sciences Enterprise Value Historical Data

The historical data trend for Solara Active Pharma Sciences's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solara Active Pharma Sciences Enterprise Value Chart

Solara Active Pharma Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Enterprise Value
Get a 7-Day Free Trial - - - - -

Solara Active Pharma Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 30,845.78

Competitive Comparison of Solara Active Pharma Sciences's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solara Active Pharma Sciences's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Solara Active Pharma Sciences's Enterprise Value falls into.



Solara Active Pharma Sciences Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Solara Active Pharma Sciences's Enterprise Value for the fiscal year that ended in Mar. 2024 is calculated as

Solara Active Pharma Sciences's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Solara Active Pharma Sciences  (NSE:SOLARAPP) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Solara Active Pharma Sciences's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=41382.373/-3388.3
=-12.21

Solara Active Pharma Sciences's current Enterprise Value is ₹41,382 Mil.
Solara Active Pharma Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-3,388 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Solara Active Pharma Sciences's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=41382.373/-2372.1
=-17.45

Solara Active Pharma Sciences's current Enterprise Value is ₹41,382 Mil.
Solara Active Pharma Sciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-2,372 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Solara Active Pharma Sciences's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=41382.373/11712.8
=3.53

Solara Active Pharma Sciences's current Enterprise Value is ₹41,382 Mil.
Solara Active Pharma Sciences's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹11,713 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Solara Active Pharma Sciences Enterprise Value Related Terms

Thank you for viewing the detailed overview of Solara Active Pharma Sciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Solara Active Pharma Sciences Business Description

Comparable Companies
Traded in Other Exchanges
Address
27, Vandaloor Kelambakkam Road, 2nd Floor. Admin Block, Melakottaiyur (Post), Keelakottaiyur Village, Chennai, TN, IND, 600 127
Solara Active Pharma Sciences Ltd is engaged in Active Pharmaceutical Ingredients manufacturer (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinod, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant and others. It also offers contract services including contract development and manufacturing, analytical services. The group has a business presence in the Asia Pacific, Europe, North America, South America, and other places, of which the majority of income is generated from the Asia Pacific countries.

Solara Active Pharma Sciences Headlines

No Headlines